Clinical Trials Browser

NIH × Stomach Neoplasms × MK 2206 × Clear all

NCT01260701 2016-01-18

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Phase 2 Completed

75 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Phase 1 Terminated

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male